DME Capital Management LP Has $9.43 Million Stake in Coya Therapeutics, Inc. (NASDAQ:COYA)

DME Capital Management LP grew its holdings in Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 29.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,646,440 shares of the company's stock after purchasing an additional 372,414 shares during the period. Coya Therapeutics comprises approximately 0.5% of DME Capital Management LP's investment portfolio, making the stock its 23rd biggest holding. DME Capital Management LP owned approximately 9.85% of Coya Therapeutics worth $9,434,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its position in shares of Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after acquiring an additional 4,777 shares during the period. XTX Topco Ltd bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $59,000. Jane Street Group LLC bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $74,000. Northern Trust Corp boosted its position in shares of Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after acquiring an additional 3,099 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $401,000. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Price Performance

COYA traded down $0.21 on Tuesday, hitting $5.93. 73,056 shares of the stock were exchanged, compared to its average volume of 85,430. Coya Therapeutics, Inc. has a 12 month low of $4.65 and a 12 month high of $10.24. The business has a 50-day moving average of $6.11 and a two-hundred day moving average of $6.22. The firm has a market capitalization of $99.18 million, a price-to-earnings ratio of -9.12 and a beta of 0.49.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, hitting the consensus estimate of ($0.44). Equities research analysts expect that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on COYA. D. Boral Capital reissued a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research report on Tuesday, April 22nd. Chardan Capital reaffirmed a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Monday, April 28th.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.